Preclinical Characterization of the Antiviral Activity of SCH 900518 (Narlaprevir), a Novel Mechanism-Based Inhibitor of Hepatitis C Virus NS3 Protease

Small-molecule hepatitis C virus (HCV) NS3 protease inhibitors such as boceprevir (SCH 503034) have been shown to have antiviral activity when they are used as monotherapy and in combination with pegylated alpha interferon and ribavirin in clinical trials. Improvements in inhibitor potency and pharm...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Tong, X., Arasappan, A., Bennett, F., Chase, R., Feld, B., Guo, Z., Hart, A., Madison, V., Malcolm, B., Pichardo, J., Prongay, A., Ralston, R., Skelton, A., Xia, E., Zhang, R., Njoroge, F. G.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society for Microbiology (ASM) 2010
Konular:
Antiviral Agents
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2876368/
https://ncbi.nlm.nih.gov/pubmed/20308381
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00135-10
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller